Stock Research for AGN

Current Price

$181.2200


Latest Update: 2018-01-19 16:00:00

High
$ 181.3900
Low
$ 181.1400
Close
$ 181.3250
Volume
72101
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

AGN Stock Chart & Research Data

The AGN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AGN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


AGN Due diligence Resources & Stock Charts

The AGN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View AGN Detailed Price Forecast - CNN Money CNN View AGN Detailed Summary - Google Finance
Yahoo View AGN Detailed Summary - Yahoo! Finance Zacks View AGN Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View AGN Trends & Analysis - Trade-Ideas Barrons View AGN Major Holders - Barrons
NASDAQ View AGN Call Transcripts - NASDAQ Seeking View AGN Breaking News & Analysis - Seeking Alpha
Spotlight View AGN Annual Report - CompanySpotlight.com OTC Report View AGN OTC Short Report - OTCShortReport.com
TradeKing View AGN Fundamentals - TradeKing Charts View AGN SEC Filings - Bar Chart
WSJ View Historical Prices for AGN - The WSJ Morningstar View Performance/Total Return for AGN - Morningstar
MarketWatch View the Analyst Estimates for AGN - MarketWatch CNBC View the Earnings History for AGN - CNBC
StockMarketWatch View the AGN Earnings - StockMarketWatch MacroAxis View AGN Buy or Sell Recommendations - MacroAxis
Bullish View the AGN Bullish Patterns - American Bulls Short Pains View AGN Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View AGN Stock Mentions - StockTwits PennyStocks View AGN Stock Mentions - PennyStockTweets
Twitter View AGN Stock Mentions - Twitter Invest Hub View AGN Investment Forum News - Investor Hub
Yahoo View AGN Stock Mentions - Yahoo! Message Board Seeking Alpha View AGN Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for AGN - SECform4.com Insider Cow View Insider Transactions for AGN - Insider Cow
CNBC View AGN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for AGN - OTC Markets
Yahoo View Insider Transactions for AGN - Yahoo! Finance NASDAQ View Institutional Holdings for AGN - NASDAQ


Stock Charts

FinViz View AGN Stock Insight & Charts - FinViz.com StockCharts View AGN Investment Charts - StockCharts.com
BarChart View AGN Stock Overview & Charts - BarChart Trading View View AGN User Generated Charts - Trading View


Latest Financial News for AGN

Why this East Bay drug maker's stock price nearly doubled last year
Posted on Friday January 19, 2018

A new wrinkle to an old treatment helped an East Bay company nearly double its stock price as it moves toward a regulatory decision on its drug for removing "frown lines" between the eyebrows. While the long-term prospects of Revance Therapeutics Inc. (RVNC) may rest more with the billion-dollar potential of its drug as a longer-lasting alternative to Botox for erasing facial wrinkles, the company is lining up clinical trials testing its drug as a therapeutic against neck spasms, a common foot ailment and other non-aesthetic conditions. "We've got no shortage of indications," said Revance President and CEO Dan Browne.


Amgen/Allergan's Avastin Biosimilar Secures EU Approval
Posted on Friday January 19, 2018

Amgen (AMGN) and Allergan's Mvasi - a biosimilar version of Roche's cancer drug, Avastin - gets marketing approval in the EU.


Johnson & Johnson’s Revenue Estimates for 4Q17
Posted on Friday January 19, 2018

As we saw in Part 1 of this series, Johnson & Johnson (JNJ) is expected to report a 10.9% growth in revenue to $20.1 billion in 4Q17 compared to 4Q16. The above chart compares the actual revenues for Johnson & Johnson since 1Q16 and estimates for 4Q17. In 4Q17, the segment is expected to report growth in operating revenues, with a favorable impact from foreign exchange.


European Commission Approves Amgen And Allergan's MVASI® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Posted on Thursday January 18, 2018

THOUSAND OAKS, Calif., Jan. 18, 2018 /PRNewswire/ -- Amgen (AMGN) and Allergan plc. (AGN) today announced that the European Commission (EC) has granted marketing authorization for MVASI® (biosimilar bevacizumab).


Buy Allergan Plc Ordinary Shares After the Earnings!
Investorplace.com - Nov 1, 2017
Here I have an 85% theoretical chance of success. But if the price falls below my strike, I will accrue losses below $127.15. Selling naked puts carries big risk.

Buy Allergan plc Ordinary Shares (AGN) Stock and Don't Look Back!
Investorplace.com - Sep 25, 2017
Wall Street has been confused about the prospects of the pharmaceutical industry for almost two years. The 2016 U.S. presidential campaign and election results wreaked havoc with their stocks.

Allergan plc Ordinary Shares (AGN) May Have Just Saved Itself Billions
Investorplace.com - Sep 14, 2017
Since 2012, as a result of the America Invents Act, biopharma companies have had to deal with an incredibly unfair situation regarding patent defense, in the form of the inter partes patent review process.

3 Big Stock Charts for Thursday: Allergan plc Ordinary Shares (AGN), Cummins ...
Investorplace.com - May 11, 2017
The market is stumbling around a bit after earnings from Macy's Inc (NYSE:M) and other retailers have traders in the profit-taking mood.

Enter a stock symbol to view the stock details.